Drug Type Induced pluripotent stem cells (iPSC), Neural stem cell therapy |
Synonyms XellSmart-411, iPSC衍生多巴胺能神经前体细胞, XS-411 + [1] |
Target- |
Action- |
Mechanism- |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 1 | China | 31 Jan 2024 | |
Primary Parkinson's disease | IND Approval | China | 11 Apr 2025 | |
Amyotrophic Lateral Sclerosis | Preclinical | United States | 22 Nov 2023 |